Jump to content
  • Member Statistics

    • Total Members
      1,230
    • Most Online
      499

    Newest Member
    Hidalia Felix
    Joined
  • Posts

    • [Idiopathic facial aseptic granuloma: A case report]. Arch Argent Pediatr. 2019 Feb 01;117(1):e56-e58 Authors: Garais JA, Bonetto VN, Frontino L, Salduna MD, Ruiz Lascano A Abstract
      Idiopathic facial aseptic granuloma is a childhood condition characterized by asymptomatic erythematous-violaceous nodules, often confused with abscesses. Its pathogenesis is unknown, but some authors have postulated its relationship with infantile rosacea. We present a case of a patient with a clinical diagnosis of idiopathic facial aseptic granuloma, with ocular involvement and a good response to oral metronidazole treatment.
      PMID: 30652457 [PubMed - in process] {url} = URL to article
    • Rosacea: Relative risk vs Absolute Risk of Malignant Comorbidities. J Am Acad Dermatol. 2019 Jan 14;: Authors: Tjahjono LA, Cline A, Huang WW, Fleischer AB, Feldman SR PMID: 30654083 [PubMed - as supplied by publisher] {url} = URL to article
    • Trigger, tripwire, flareup and flush. These are probably the four most common terms used when discussing rosacea. Because of poor communication and rosaceans not understanding what there terms actually mean much confusion results, adding to the already confusing dilemma of rosacea understanding. So to set the record: 

      Flare up according to the NRS is "a more intense outbreak of redness, bumps or pimples.."  

      Tripwire or Trigger is the same thing according to the NRS who uses these words interchangeably and states that both terms mean, "factors that may cause a rosacea sufferer to experience a flare-up—a more intense outbreak of redness, bumps or pimples. [1]

      A medical dictionary source defines flush as: flush 1. transient, episodic redness of the face and neck caused by certain diseases, ingestion of certain drugs or other substances, heat, emotional factors, or physical exertion. See also erythema. [2]

      A blush is a flush usually caused by psychological factors. A flush can be caused by a any number of factors as noted above including psychological factors. 

      The reason this is brought up is that while most rosaceans confuse flushing with a flare up there are rosaceans who report having a flare up of rosacea and DO NOT FLUSH. These ones are admittedly fewer in number, and flushing is usually associated with a flare up, but nevertheless demonstrates that flushing is not necessarily a rosacea flare up. One could flush or blush and the skin returns to normal in a rosacea sufferer. Flushing does not NECESSARILY mean a rosacea flare up and it only means that it MAY produce a rosacea flare up. Those who think flushing is rosacea is like thinking pimples mean you have rosacea (or for that matter, believing that erythema is rosacea). There is more to a diagnosis of rosacea than simply having pimples and erythema (see Diagnosis). For example, one could have erythema and have Atopic Dermatitis, not rosacea.  Flushing is one of the signs or symptoms usually associated with rosacea, but not necessarily required. Pimples are associated with rosacea but not necessarily required, i.e., Phenotype 2. Rosacea is always associated with redness or erythema.  Hopefully, if rosaceans understand these terms, trigger, tripwire, flareup and flush better, we will all be on the same page when we discuss rosacea. 

      End Notes

      [1] Coping With Rosacea, National Rosacea Society, page 1

      [2] Dorland’s Illustrated Medical Dictionary
    • Trends in Oral Antibiotic Prescription in Dermatology, 2008 to 2016. JAMA Dermatol. 2019 Jan 16;: Authors: Barbieri JS, Bhate K, Hartnett KP, Fleming-Dutra KE, Margolis DJ Abstract
      Importance: Dermatologists prescribe more oral antibiotic courses per clinician than any other specialty, and this use puts patients at risk of antibiotic-resistant infections and antibiotic-associated adverse events.
      Objective: To characterize the temporal trends in the diagnoses most commonly associated with oral antibiotic prescription by dermatologists, as well as the duration of this use.
      Design, Setting, and Participants: Repeated cross-sectional analysis of antibiotic prescribing by dermatologists from January 1, 2008, to December 31, 2016. The setting was Optum Clinformatics Data Mart (Eden Prairie, Minnesota) deidentified commercial claims data. Participants were dermatology clinicians identified by their National Uniform Claim Committee taxonomy codes, and courses of oral antibiotics prescribed by these clinicians were identified by their National Drug Codes.
      Exposures: Claims for oral antibiotic prescriptions were consolidated into courses of therapy and associated with the primary diagnosis from the most recent visit. Courses were stratified into those of extended duration (>28 days) and those of short duration (≤28 days).
      Main Outcomes and Measures: Frequency of antibiotic prescribing and associated diagnoses. Poisson regression models were used to assess for changes in the frequency of antibiotic prescribing over time.
      Results: Between 2008 and 2016 among 985 866 courses of oral antibiotics prescribed by 11 986 unique dermatologists, overall antibiotic prescribing among dermatologists decreased 36.6% (1.23 courses per 100 visits) from 3.36 (95% CI, 3.34-3.38) to 2.13 (95% CI, 2.12-2.14) courses per 100 visits with a dermatologist (prevalence rate ratio for annual change, 0.931; 95% CI, 0.930-0.932), with much of this decrease occurring among extended courses for acne and rosacea. Oral antibiotic use associated with surgical visits increased 69.6% (2.73 courses per 100 visits) from 3.92 (95% CI, 3.83-4.01) to 6.65 (95% CI, 6.57-6.74) courses per 100 visits associated with a surgical visit (prevalence rate ratio, 1.061; 95% CI, 1.059-1.063).
      Conclusions and Relevance: Continuing to develop alternatives to oral antibiotics for noninfectious conditions, such as acne, can improve antibiotic stewardship and decrease complications from antibiotic use. In addition, the rising use of postoperative antibiotics after surgical visits is concerning and may put patients at unnecessary risk of adverse events. Future studies are needed to identify the value of this practice and the risk of adverse events.
      PMID: 30649187 [PubMed - as supplied by publisher] {url} = URL to article
    • Exploring the potential for rosacea therapeutics of siRNA dispersion in topical emulsions. Exp Dermatol. 2019 Jan 16;: Authors: Colombo S, Harmankaya N, Water JJ, Bohr A Abstract
      Rosacea is a prevalent skin condition dependent on the individual genetic profile. The current pharmacological management of this condition is mostly based on small molecule drugs predominately effective in ameliorating the inflammatory condition. Emerging molecular approaches could present an opportunity for managing rosacea conditions at transcriptomic level, and in the future allow personalized approaches. RNA medicines, such as small RNA interference (siRNA), could provide a flexible and applicable tool reaching this aim. However, the topical siRNA delivery by dermatological emulsions, commonly used in the daily management of rosacea, is still largely unexplored. Consequently, RNA interference application to rosacea was defined on molecular bases by genetic expression meta-data analysis. Based on this, an siRNA directed against TLR2 was designed and validated in vitro on murine macrophages and fibroblasts. Next, siRNA was dispersed in the continuous phase of emulsions and was characterized for commonly used dermatologic bases. Finally, the potential delivery performance of the topical emulsions was tested in vivo on healthy Balb/c mice. It was found that the interaction of siRNA with combination of excipients such as urea and glycerol, is likely to favor the siRNA delivery, inducing genetic silencing of TLR2. These findings provide a foundation for the future development of topical RNA-based dispersions for topical molecular medicines, by emphasizing on the formulation and therapeutic-based opportunities with dermatological treatments. This article is protected by copyright. All rights reserved.
      PMID: 30650201 [PubMed - as supplied by publisher] {url} = URL to article
    • At CES 2019, there is a new light device mentioned by Gizmodo , the Opté’s beauty wand and all you do is watch this video below to see how it works:  If anyone purchases one of these wands, please post your results in this thread. Becky gives a review of the wand here. 
    • "Photodynamic therapy is mainly used in dermatology to treat skin tumors, precancerous lesions, and condyloma acuminatum. Due to its excellent tissue selectivity, easy operation and good cosmetic effect, it has been gradually applied to the treatment of various non-neoplastic skin diseases, such as verruca acuminata, acne, rosacea, chronic skin ulcer, fungal diseases, keloid, and so on." Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Dec 28;43(12):1380-1383. doi: 10.11817/j.issn.1672-7347.2018.12.016.
      Advancement in phodynamic therapy for non-neoplastic skin diseases.
      [Article in Chinese; Abstract available in Chinese from the publisher]
      Zhan Y, Xiao R, Zhang Z.
       
    • Related Articles [Advancement in phodynamic therapy for non-neoplastic skin diseases]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Dec 28;43(12):1380-1383 Authors: Zhan Y, Xiao R, Zhang Z Abstract
      Photodynamic therapy is mainly used in dermatology to treat skin tumors, precancerous lesions, and condyloma acuminatum. Due to its excellent tissue selectivity, easy operation and good cosmetic effect, it has been gradually applied to the treatment of various non-neoplastic skin diseases, such as verruca acuminata, acne, rosacea, chronic skin ulcer, fungal diseases, keloid, and so on. Here is the review on the advancement in photodynamic therapy for non-neoplastic skin diseases.
      PMID: 30643057 [PubMed - in process] {url} = URL to article
    • As you can see, Stephan_J wrote the OP November 27, 2017 and never replied to my question. You can purchase Arquebuse Water from skinsentials, a company in Australia and it is pricey. If you purchase and try it, please post your results in this thread. Wish Amazon would sell it. I haven't tried Amazon Australia. 
    • Acyclovir, an antiviral medication, has been used to treat rosacea and the results according to one paper is "a patient with rosacea who was completely symptom free during two courses of treatment with acyclovir, which was prescribed for the patient’s herpes..." [1]. Acyclovir has been used to treat Pityriasis rosea, a type of skin rash, reported in one paper that may be effective. [2] Nellukas, at RF reports taking two 200 mg tablets twice daily after meals and states, "To my surprise, rosacea started to recede a few days after I started the regimen!!" End Notes [1] American Journal of Clinical Dermatology
      December 2017, Volume 18, Issue 6, pp 845–846 • Full Text 
      Improvement of Rosacea During Acyclovir Treatment: A Case Report
      Zohreh Sadat Badieyan, Sayed Shahabuddin Hosein [2] J Am Acad Dermatol. 2006 Jan;54(1):82-5.
      Use of high-dose acyclovir in pityriasis rosea.
      Drago F, Vecchio F, Rebora A.
    • What type of Rosacea you have had Stephan_J What phenotype?  
    • Clinical effectiveness of novel rosacea therapies. Curr Opin Pharmacol. 2019 Jan 10;46:14-18 Authors: Feaster B, Cline A, Feldman SR, Taylor S Abstract
      Rosacea is a common inflammatory skin disease that is difficult to manage because of the unknown etiology and due to its variable manifestations. These facts and the few new available treatment options make it difficult to select a really effective treatment. This review aims to assess the efficacy and safety of novel treatment options for rosacea. The topical alpha adrenergic agonist oxymetazoline reduces rosacea-related erythema. Topical ivermectin improves lesion count, inflammation, and maintenance of remission of rosacea compared to topical metronidazole. Procedural therapies including pulsed dye laser, radiofrequency, and dual frequency ultrasound are promising as both monotherapies or in combination. Although there are several effective treatment modalities for rosacea management, treatments options should be tailored for the specific clinical scenario.
      PMID: 30639950 [PubMed - as supplied by publisher] {url} = URL to article
    • Classifying signs and symptoms of dry eye disease according to underlying mechanism via the Delphi method: the DIDACTIC study. Br J Ophthalmol. 2019 Jan 12;: Authors: Labetoulle M, Bourcier T, Doan S, DIDACTIC group Abstract
      BACKGROUND/AIMS: Dry eye disease (DED) is categorised by pathophysiology as aqueous deficient dry eye (ADDE), evaporative dry eye (EDE) or mixed. Treatment should be tailored to DED pathophysiology, but this is challenging to determine. This Delphi consultation aimed to categorise and weight signs and symptoms to help identify the evaporative or aqueous deficient DED origin.
      METHODS: A panel of French DED experts created an initial list of 77 DED signs and symptoms. In a Delphi consultation, experts categorised items by DED pathophysiology. Likert scoring was used to indicate whether items were strongly or moderately indicative of ADDE or EDE. Items could also be judged non-applicable to DED, with the opportunity to suggest alternative diagnoses.
      RESULTS: Experts attributed 19 items (of which 11 were strongly indicative) to a pathophysiology of EDE and 12 items (of which four were strongly indicative) to ADDE. Items scored strongly indicative with agreement >90% for EDE were previous chalazia, rosacea/rhinophyma, telangiectasias of eyelid margin and thick non-expressible meibomian gland secretions, and for ADDE were Sjögren syndrome or associated disease, and Schirmer <5 mm after 5 min (without anaesthesia). Seventeen items indicated neither pathophysiology and 18 items were found to be suggestive of alternative diagnoses.
      CONCLUSIONS: This Delphi consultation categorised signs and symptoms, using an innovative weighting system to identify DED pathophysiology. An algorithm integrating the weighting of each sign and symptom of an individual patient would be valuable to help general ophthalmologists to classify the DED subtype and tailor treatment to DED underlying mechanism.
      PMID: 30636211 [PubMed - as supplied by publisher] {url} = URL to article
    • Lucy at RF reports taking these three oral non prescriptions that she says helps:  Viralex BePure (NZ brand) Omega 3 BePure Probiotic  Fish Oil plus vitamins 
    • Related Articles Recent advances in understanding and managing rosacea. F1000Res. 2018;7: Authors: Buddenkotte J, Steinhoff M Abstract
      Rosacea is a common chronic inflammatory skin disease of the central facial skin and is of unknown origin. Currently, two classifications of rosacea exist that are based on either "preformed" clinical subtypes (erythematotelangiectatic, papulopustular, phymatous, and ocular) or patient-tailored analysis of the presented rosacea phenotype. Rosacea etiology and pathophysiology are poorly understood. However, recent findings indicate that genetic and environmental components can trigger rosacea initiation and aggravation by dysregulation of the innate and adaptive immune system. Trigger factors also lead to the release of various mediators such as keratinocytes (for example, cathelicidin, vascular endothelial growth factor, and endothelin-1), endothelial cells (nitric oxide), mast cells (cathelicidin and matrix metalloproteinases), macrophages (interferon-gamma, tumor necrosis factor, matrix metalloproteinases, and interleukin-26), and T helper type 1 (T H1) and T H17 cells. Additionally, trigger factors can directly communicate to the cutaneous nervous system and, by neurovascular and neuro-immune active neuropeptides, lead to the manifestation of rosacea lesions. Here, we aim to summarize the recent advances that preceded the new rosacea classification and address a symptom-based approach in the management of patients with rosacea.
      PMID: 30631431 [PubMed - in process] {url} = URL to article
    • Sure,   No worries mate I didn't know where to put it myself, just wanted to reach as many people as possible. If even one person try this way because he /she reads my testimony and will feel better after that would be great. Also if somebody has similiar expieriences it would be great that we can share it.  
    • RedMage,  Welcome to the RRDi forum. You have a detailed history and it appears you are coming closer to regulating your flushing better. We posted about Colin Dahl's paper here in November 2017.  I have collected together a list of treatments used for flushing avoidance, if you haven't read this page already. There a number of other posts in the following:  Forum Home >  Forums > Public Forum > Rosacea Topics > Trigger Avoidance > Blushing & Flushing Triggers There is a thread at RF with a similar theme, Warm room flush theory revisited. If you would permit me, I think your post should be in the above category rather than in Rosacea in Remission since you seem to still have rosacea not completely in remission. Let me know if that is ok with you. 
    • Hi all, This will be my first post on this forum so I will start with short version of my story as a Rosacea sufferer.                    Normally I m living in Poland and I have been living in Australia for almost a year now. I started to notice that I have problems with this condition when I was 16 (today I have 32, so this is a long-standing problem). During this time, I tried many available therapies prescribed to me by doctors, dermatologists or found on the internet. I lost a lot of money and time on creams, tablets, lasers  (I had over 20 IPLs alone). Nothing helped in the long run. In the case of creams even worsened the case because at the moment I am not able to take any even delicate creams without hugly increasing my redness. Lasers could help mildly for a while but later the cheeks returned to their initial state. The tablets helped with flushing but the side effects could be very unpleasant and the red color remained. Some of the medications were able to exacerbate my condition. And with this short intruduction behind us lets go to the main dish.                       Observing my condition over the years, I noticed that my condition is improving during the summer period and worsens during autumn and winter. I thought it must be related to the amount of sun, so whenever I could I was exposing to the sun's rays. Tan actually partially concealed my ailment, although when it came down my skin was even worse than before. Last year, I went on a work & holiday visa to Australia, I chose Brisbane as a destination because I wanted my skin to get as much sun as possible and stay tanned all the time.
      As I quickly learned, because the sun here in Australia is much more biting, it was not the right approach. And mostly I was staying red all the time.
      During that time, at the forum rosaceagroup.org, I read the article "Warm room flush theory revisited" which directed to Colin Dahl's book "HEAT REGULATION AND THE WARM ROOM FLUSH PHENOMENON"
      The author is / was also rosacea sufferer. However, he managed to overcome his illness with the help of the regime he introduced. What is important is doesn't cost money, no wonderful creams or medicines. Even a laser is an optional matter here. However, my observations and Colin's observations are very convergent.                        I also wrote to him on LinkedIn to find out more details and he was so kind that he answered my questions and meticulously answered all of them.
      I started applying the regimen from September 2018, now 4 months of testing are behind me. Unfortunately, due to my work and housing conditions, I am not able to 100% stick to the presented regime. I stopped using chemistry and replaced it with an unscented soap, the same with sunscreen. A simple cream with zinc or zinc oxiade, at least SPF 30+. I trying to make the temperature in the room in which I sleep did not fall below 22 degrees. I also avoid staying in places where there are major temperature changes. This is not easy. I would say it is actually very hard. Ithink I making the plan is about 50%. The effects, however, are visible now and it seems to me that these are the best effects I have ever had even after using the most expensive lasers were not half as good.                       First of all, flushing was practically eliminated. I remember only 2 such attacks recently, but it was due to the fact that for 2 weeks I was on a trip in Cruise Ship in the South Pacific and the temperature between the islands and the air-conditioned interior plus wind and that I did not watch too well to the regime caused that after these two weeks I had this problems.
      The skin seems calmer although Its still far from its natural color (compering with the color on forehead for instance). For this I have to reduce the infrastructure of blood vessels and reverse angiogenesis. According to the author, it took him 18 months so surely I have a long way to go. Though if I will be able after I return to Poland to sustain even this result my life would be so much better compared to that it used to be. Please let me know if any of you also were trying this approach or for any other questions.   
    • There is a clinical trial going on using PAC-14028 Cream for Atopic Dermatitis (Eczema) being done by Amorepacific Corporation. Initial results seem promising [1].  End Notes  [1] British Journal of Dermatology
      Efficacy and safety of PAC‐14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild‐to‐moderate atopic dermatitis: a phase IIb randomized trial
      Y.W. Lee  C.‐H. Won  K. Jung  H.‐J. Nam  G. Choi  Y.‐H. Park  M. Park  B. Kim
    • red devil at RF [Post no 55] found another treatment using TXA, DERMO PHARMA DNA CREAM TRANEXAMIC ACID + COLLAGEN, by Dermapharma (Switzerland), which we await the results. 
    • Lasers Surg Med. 2018 Oct 12. doi: 10.1002/lsm.23023. [Full Text with pictures]
      The toxic edge-A novel treatment for refractory erythema and flushing of rosacea.
      Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O.

      Abstract
      PURPOSE:
      Rosacea is a common, chronic facial skin disease that affects the quality of life. Treatment of facial erythema with intradermal botulinum toxin injection has previously been reported. The primary objective of the study was the safety and efficacy of thermal decomposition of the stratum corneum using a novel non-laser thermomechanical system (Tixel, Novoxel, Israel) to increase skin permeability for Botulinum toxin in the treatment of facial flushing of rosacea.
      METHODS:
      A retrospective review of16 patients aged 23-45 years with Fitzpatrick Skin Types II to IV and facial erythematotelangiectatic rosacea treated by Tixel followed by topical application of 100 U of abobotulinumtoxin. A standardized high-definition digital camera photographed the patients at baseline and 1, 3, and 6 months after the last treatment. Objective and subjective assessments of the patients were done via Mexameter, the Clinicians Erythema Assessment (CEA), and Patients self-assessment (PSA) scores and the dermatology life quality index (DLQI) validated instrument.
      RESULTS:
      The average Maxameter, CEA, and PSA scores at 1, 3, and 6 months were significantly improved compared with baseline (all had a P-value <0.001). DLQI scores significantly improved with an average score of 18.6 at baseline at 6 months after treatment (P < 0.001). Self-rated patient satisfaction was high. There were no motor function side-effects or drooping.
      CONCLUSION:
      Thermal breakage of the stratum corneum using the device to increase skin permeability for botulinum toxin type A in the treatment of facial flushing of rosacea seems both effective and safe. Lasers Surg. Med. © 2018 Wiley Periodicals, Inc.
    • Related Articles Nickel Sensitivity In Rosacea Patients: A Prospective Case Control Study. Endocr Metab Immune Disord Drug Targets. 2019 Jan 01;: Authors: Çifci N Abstract
      BACKGROUND: Rosacea is a frequently seen chronic disease that allergens, some foods and beverages are known to trigger symptoms of rosacea.
      OBJECTIVE: We aimed to assess if nickel sensivity is more common in rosacea patients than normal population.
      METHOD: Fourty patients with rosacea and 40 healthy age and sex matched volunteers were included in the study. From European standard patch test series, test units with nickel were applied on the skin of the upper back. According to the scheme of the International Contact Dermatitis Research Group (ICDRG), test results were evaluated at 48th, 72th and 96th hours. Seven days later, reevaluation was done for late reactions. Statistical analyses were done by using Statistics package for Social Sciences (SPSS) 17 package program and p<0.05 was accepted as statistically significant.
      RESULTS: Female/male ratio was 34/6 in patient group and 32/8 in control group. Mean age of patient group and the control group were 39.97±12.65 (18-65 years), 40.82±11.79 (19-68 years), respectively. Age and sex distributions were found to be statistically similar. Nickel allergy in the patient and control group was found to be 52.5%, 22.5% respectively and the difference between groups was statistically significant (p=0. 006).
      CONCLUSION: Our results showed that there may be an association between nickel sensitivity and rosacea. Nickel sensitivity may be one of the underlying pathology or a triggering factor of the rosacea. Nickel restricted diet and avoiding use of nickel containing jewellery and piercings, may extend the remission periods.
      PMID: 30621570 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Melkersson-Rosenthal syndrome: a case report of a rare disease with overlapping features. Allergy Asthma Clin Immunol. 2019;15:1 Authors: Cancian M, Giovannini S, Angelini A, Fedrigo M, Bendo R, Senter R, Sivolella S Abstract
      Background: Melkersson-Rosenthal syndrome (MRS) is a rare, neuro-mucocutaneous disease which presents as orofacial swelling, facial palsy and fissured tongue. These symptoms may occur simultaneously or, more frequently, with a oligosymptomatic or monosymptomatic pattern. Swelling, that is the most common initial finding, may mimic hereditary or acquired angioedema, a disorder caused by histamine or bradykinin-mediated plasma-leakage affecting subcutaneous and/or submucosal tissue. The differential diagnosis of MRS includes also chronic inflammatory and infective diseases characterized by granulomatous infiltration, as well as rosacea, contact dermatitis, allergic reactions and Bell's palsy.
      Case presentation: A 71-year old, non-allergic female patient with no familial and personal history of angioedema presented, a few days after a possible herpes simplex or varicella-zoster virus infection, with monolateral facial paraesthesia and lower lip edema. After temporary remission of symptoms on oral steroids and antihistamines, she showed swelling recurrence refractory to valaciclovir therapy and a subsequent course of antihistamines. The clinical picture and a previous history of non-Hodgkin lymphoma prompted us to rule out an acquired form of paraneoplastic, C1-inhibitor (C1-INH) deficiency: C1q and both antigen and functional C1-INH tested normal, whilst we found low plasma levels of C3 and C4 possibly related to the parallel detection of antiphospholipid antibodies. Thus, we hypothesized a non-histaminergic, idiopathic form of angioedema and planned further therapy with tranexamic acid and the leukotriene receptor antagonist montelukast. Treatment failure with both drugs finally suggested a Melkersson-Rosenthal syndrome, which was confirmed by histologic findings of non caseating granulomas on lip biopsy.
      Conclusion: Melkersson-Rosenthal syndrome may occur with rather non-specific symptoms and overlap with alternative conditions, including recurrent angioedema. No specific biomarkers for MRS exist and clinical diagnosis is often of exclusion. The finding of complement or immune alterations, as in our patient, may be further confounding and justify the need for skin or mucosal biopsy to establish a correct diagnosis and prescribe targeted therapy.
      PMID: 30622569 [PubMed] {url} = URL to article
    • Discovered Acne and Rosacea Society of Canada website which says on its 'about us' page:  "The Acne and Rosacea Society of Canada, a national, not for profit organization led by Canadian dermatologists, offers hope and help to sufferers by providing independent, reputable and current information on these conditions and raising awareness." On its Corporate Sponsor page it shows Galderma as a Silver Level sponsor, Bayer Cipher Pharmaceuticals as a Bronze level, and Altius Healthcare as a Friend level. We will be monitoring and reviewing this Canadian non profit and investigate what it spends its funds on and report in this thread. 
    • How is the treatment going now?
    • You've done a great job. It looks really good.
    • Thank you very much for your analysis. It's very useful.
    • The RRDi has established a LinkedIn company page. 
    • Related Articles Dermoscopy of Common Inflammatory Disorders. Dermatol Clin. 2018 Oct;36(4):359-368 Authors: Sgouros D, Apalla Z, Ioannides D, Katoulis A, Rigopoulos D, Sotiriou E, Stratigos A, Vakirlis E, Lallas A Abstract
      In addition to its "traditional" application for the early diagnosis of melanoma and nonmelanoma skin cancers, dermoscopy gains appreciation in fields beyond dermato-oncology. Nowadays, dermoscopy has been established as a reliable adjunctive tool to the everyday clinical practice of general dermatology. Morphology and distribution of vascular structures, background colors, follicular abnormalities, and the presence of scales are important features that should be evaluated. Clinical examination remains the undoubted mainstay of diagnosis in inflammatory and infectious diseases.
      PMID: 30201145 [PubMed - indexed for MEDLINE] {url} = URL to article
    • Related Articles Microneedling with Biologicals: Advantages and Limitations. Facial Plast Surg Clin North Am. 2018 Nov;26(4):447-454 Authors: Duncan DI Abstract
      Microneedling is a popular and cost-effective treatment with little down time. The application of topical agents to enhance outcomes is common practice. Microchannels created with nonthermal needling close at 4 hours to 6 hours due to fibrin plugs. Channels created with thermal needling or fractional laser stay open longer and enhance drug or biological uptake more due to the dermal sponge injury pattern that is created. Nonthermal microneedling devices may need Food and Drug Administration clearance, which also notes that dermaceuticals should be considered drugs in many cases.
      PMID: 30213426 [PubMed - indexed for MEDLINE] {url} = URL to article
    • Related Articles Morbihan disease: treatment difficulties and diagnosis: a case report. Pan Afr Med J. 2018;30:226 Authors: Aboutaam A, Hali F, Baline K, Regragui M, Marnissi F, Chiheb S Abstract
      Morbihan disease (MD) is a rare entity. Its nosography is unclear and its therapeutic management is difficult. We report a new case of MD. We report a case of a 51-year-old patient consulted in our department for a one year facial edema, erythema and papules reported by him, for which the patient was treated with cyclins, local and general corticotherapy, without improvement. The clinical examination found an important edema of the front and eyelids with an erythema of the cheeks covered with a few telangiectasias. The clinical, biological and histological findings lead to a diagnosis of Morbihan disease after excluding other diseases. Due to previous therapeutic failures, the patient was put on isotretinoin and furosemide with slight improvement. The particularity of our observation lies in the rarity and especially in the therapeutic difficulties encountered during this disease.
      PMID: 30574244 [PubMed - indexed for MEDLINE] {url} = URL to article
    • Apparently the club feature allows you to setup your own 'club' or blog and totally control it yourself. You have to be a member of the RRDi to do this but you can make it totally public and allow anyone to comment a reply, so that means anyone could put whatever they want, which may mean I will change this later to RRDi members only can comment. So let's see what happens. 
    • Gallo et al whose research published in Nature Medicine in 2007 that suggested "an explanation for the pathogenesis of rosacea by demonstrating that an exacerbated innate immune response can reproduce elements of this disease" involving cathelicidin (particularly Peptide LL-37), Vitamin D3, and Alarmins has applied for a patent (United States Patent Application 20160030386), PREVENTION OF ROSACEA INFLAMMATION. [1] The patent is a long read and not for the timid or shy to read through. The nutshell version is a patent for treating rosacea inflammation with mast cell stabilizers, (ie., lodoxamide, nedocromil, cromolyn, pemirolast, pharmaceutical salts), as well as, neuropetide antagonists, a serine protease inhibitor,  a vitamin D3 antagonist, including combinations of these treatments.  End Notes [1] Images and tables/graphs with results
      http://www.freepatentsonline.com/20160030386.pdf
    • Of course, not all skin care trends are bad news, said Dhaval Bhanusali, a dermatologist in New York. "I don't think people should ignore trends, but they should always proceed with caution," he told INSIDER. "Just because something worked for one person, doesn't mean it will work for another. You have to be careful." 10 popular skin-care trends dermatologists say you should avoid
      Maddy Sims, Business Insider
×